Evidence map›Paper›PMID 26213579›Full record

Trial reportAlzheimer's research & therapy2015

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease.

Anne Rijpma, Olga Meulenbroek, Anneke M J van Hees, John W C Sijben, Bruno Vellas, Raj C Shah, David A Bennett, Philip Scheltens, Marcel G M Olde Rikkert

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Alzheimer's research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021
    Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Is Alzheimer's Disease Risk Modifiable?Journal of Alzheimer's disease : JAD · 2019
    Review
  14. The Medicinal Plant PairFrontiers in pharmacology · 2019
    Article
  15. Article
  16. Review
  17. The essential elements of Alzheimer's disease.The Journal of biological chemistry
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Anne RijpmaRadboud Alzheimer Center, Department of Geriatric Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Olga MeulenbroekRadboud Alzheimer Center, Department of Geriatric Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Anneke M J van HeesNutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
John W C SijbenNutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
Bruno VellasGerontopole, INSERM U1027, Toulouse, France.
Raj C ShahRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL USA.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL USA.
Philip ScheltensAlzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.
Marcel G M Olde RikkertRadboud Alzheimer Center, Department of Geriatric Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Radboud Institute for Molecular Life Sciences · NLNutricia Research (Netherlands) · NLRush University Medical Center · USAmsterdam UMC Location Vrije Universiteit Amsterdam · NLUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCirculating levels of uridine, selenium, vitamins B12, E and C, folate, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been shown to be lower in patients with Alzheimer's disease (AD) than in healthy individuals. These low levels may affect disease pathways involved in synapse formation and neural functioning. Here, we investigated whether, and to what extent, circulating levels of micronutrients and fatty acids can be affected by oral supplementation with Souvenaid (containing a specific nutrient combination), using data derived from three randomized clinical trials (RCT) and an open-label extension (OLE) study with follow-up data from 12 to 48 weeks.

methodsSubjects with mild (RCT1, RCT2) or mild-to-moderate AD (RCT3) received active or control product once daily for 12-24 weeks or active product during the 24-week OLE following RCT2 (n = 212-527). Measurements included plasma levels of B vitamins, choline, vitamin E, selenium, uridine and homocysteine and proportions of DHA, EPA and total n-3 long-chain polyunsaturated fatty acids in plasma and erythrocytes. Between-group comparisons were made using t tests or non-parametric alternatives.

resultsWe found that 12-24-week active product intake increased plasma and/or erythrocyte micronutrients: uridine; choline; selenium; folate; vitamins B6, B12 and E; and fatty acid levels of DHA and EPA (all p < 0.001). In the OLE study, similar levels were reached in former control product/initial active product users, whereas 24-week continued active product intake showed no suggestion of a further increase in nutrient levels.

conclusionsThese data show that circulating levels of nutrients known to be decreased in the AD population can be increased in patients with mild and mild-tomoderate AD by 24-48-week oral supplementation with Souvenaid. In addition, to our knowledge, this is the first report of the effects of sustained dietary intake of uridine monophosphate on plasma uridine levels in humans. Uptake of nutrients is observed within 6 weeks, and a plateau phase is reached for most nutrients during prolonged intake, thus increasing the availability of precursors and cofactors in the circulation that may be used for the formation and function of neuronal membranes and synapses in the brain.

Indexed as

Dietary SupplementsFood, FormulatedAgedAlzheimer DiseaseDouble-Blind MethodFatty AcidsFemaleHumansInflammationMaleMicronutrientsNeuroprotective AgentsOxidative StressSeverity of Illness IndexTreatment OutcomeFatty AcidsMicronutrientsNeuroprotective Agents

Identifiers

PMID26213579
PMCPMC4513634
OpenAlexW1604682243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.